| Status | Topic selection |
| Technology type | Medicine |
| Decision | Not selected |
| Reason for decision | Not eligible for Health Technology Evaluation guidance |
| Further information | The 2024 voluntary scheme for branded medicines, pricing, access and growth states that NICE will continue to evaluate all new active substances and significant indications, except where there is a clear rationale not to do so. Decision makers have concluded that the clear rationale to not evaluate this product is due to regulatory approval not expected in the next 24 months. Therefore, this technology fall out of remit for selection as per section 3.1 of the NICE-Wide prioritisation manual. |
| ID number | 12125 |
Email enquiries
- If you have any queries please email topic.selection@nice.org.uk
For further information on how we select topics for development, please see our page about topic selection